Comparable stake leader
Ikarian Capital, LLC
SEC ownership of NextCure, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001661059.
Disclosed value leader
Ikarian Capital, LLC
Comparable rows
28/46
Latest evidence
31 Mar 2026
- Public ticker
- NXTC on Nasdaq
- Parsed ownership sources
- 13D/G, 13F, and 3/4/5
- Largest SEC-reported holder
- Ikarian Capital, LLC
- Latest 13D/G holder
- Ikarian Capital, LLC
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0001661059
- Issuer location
- Beltsville, MD
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of NextCure, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Ikarian Capital, LLC
Disclosed value leader
Ikarian Capital, LLC
Comparable rows
28/46
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
18 rows are not safely comparable across share classes.
13D/G row: Ikarian Capital, LLC
Showing 1-8 of 46 holder rows.
Quick read
Ikarian Capital, LLC leads the comparable SEC ownership view at 10%.
28 of 46 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ikarian Capital, LLC's linked filing trail.
Comparable ownership
Top 5
Ikarian Capital, LLC
10%
Affinity Asset Advisors, LLC
10%
Squadron Capital Management LLC
9.9%
Simcere Zaiming, Inc.
9.4%
Sofinnova Venture Partners IX, L.P.
7.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 46 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Ikarian Capital, LLC |
13D/G
13F
Company
|
10%
|
$4,715,825
363,035 shares
|
$0 | 31 Dec 2025 |
| Affinity Asset Advisors, LLC |
13D/G
13F
Company
|
10%
|
$4,375,018
348,607 shares
|
+$1,966,899 | 22 Jan 2026 |
| Squadron Capital Management LLC |
13D/G
13F
Squadron Master Fund LP · Company
|
9.9%
|
$3,521,940
271,127 shares
|
+$1,263,485 | 31 Dec 2025 |
| Simcere Zaiming, Inc. |
13D/G
3/4/5
10%+ Owner
|
9.4%
|
$152,386
338,636 shares
|
$0 | 31 Dec 2025 |
| Sofinnova Venture Partners IX, L.P. |
13D/G
Sofinnova Venture Partners IX, L.P. ("SVP IX")
|
7.1%
|
$2,947,939
222,654 shares
|
$0 | 19 Dec 2025 |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13D/G
13F
Company
|
5%
|
$2,286,980
176,057 shares
|
$0 | 31 Dec 2025 |
| CITIGROUP INC |
13D/G
13F
Citigroup Global Markets Inc. · Company
|
4.3%
|
$506,181
1,205,193 shares
|
$0 | 31 Mar 2025 |
| PFIZER INC |
13F
13D/G
Company · Pfizer Inc. (IRS Identification No.: 13-5315170)
|
3%
from 13D/G
|
$1,535,074
153,354 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 10 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to NextCure, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
Simcere Zaiming, Inc.
Net 12M change
$0
Latest report
30 Jan 2026
Recent insider transactions for NextCure, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Kevin G. Shaw | NXTC | Employee Stock Option (Right to Buy) | Award | 8,270 | 8,270 | 30 Jan 2026 | Direct | |||
| Sourav Kundu | NXTC | Employee Stock Option (Right to Buy) | Award | 8,270 | 8,270 | 30 Jan 2026 | Direct | |||
| Timothy Mayer | NXTC | Employee Stock Option (Right to Buy) | Award | 14,670 | 14,670 | 30 Jan 2026 | Direct | |||
| Udayan Guha | NXTC | Employee Stock Option (Right to Buy) | Award | 14,670 | 14,670 | 30 Jan 2026 | Direct | |||
| Steven P. Cobourn | NXTC | Employee Stock Option (Right to Buy) | Award | 14,670 | 14,670 | 30 Jan 2026 | Direct | |||
| Michael Richman | NXTC | Employee Stock Option (Right to Buy) | Award | 38,190 | 38,190 | 30 Jan 2026 | Direct | |||
| John G. Houston | NXTC | Stock Option (Right to Buy) | Award | 18,700 | 18,700 | 20 Jun 2025 | Direct | |||
| Elaine V Jones | NXTC | Stock Option (Right to Buy) | Award | 18,700 | 18,700 | 20 Jun 2025 | Direct | |||
| Kabakoff David S | NXTC | Stock Option (Right to Buy) | Award | 28,050 | 28,050 | 20 Jun 2025 | Direct | |||
| Anne Elizabeth Borgman | NXTC | Stock Option (Right to Buy) | Award | 18,700 | 18,700 | 20 Jun 2025 | Direct | |||
| Stephen W. Webster | NXTC | Stock Option (Right to Buy) | Award | 18,700 | 18,700 | 20 Jun 2025 | Direct | |||
| Ellen Feigal | NXTC | Stock Option (Right to Buy) | Award | 18,700 | 18,700 | 20 Jun 2025 | Direct |
* marks a reported price that did not pass the local price check.